Global Leader in Specialty Therapeutics Selects Kneat to Digitize Validation
January 09, 2025 17:17 ET
|
kneat.com, inc.
Leading European global therapeutics company more than 20,000 people selects Kneat to digitize its validation processes.
Global Medical Devices Manufacturer Selects Kneat to Digitize Validation
October 31, 2024 17:13 ET
|
kneat.com, inc.
Kneat signs a global and diverse medical devices manufacturer for digital validation.
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
October 09, 2024 08:00 ET
|
Evaxion Biotech
Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets Strongest outcomes are generated by the top-ranked...
Kneat Announces Record Revenue for Second Quarter 2024
August 06, 2024 17:17 ET
|
kneat.com, inc.
Kneat's Q2 2024 Growth Accelerates YoY, with Revenue up 45%, Annual Recurring Revenue up 60%, Gross Profit up 63%
Kneat Announces Record Revenue for First Quarter 2024
May 08, 2024 17:33 ET
|
kneat.com, inc.
Kneat maintains 35% year-over-year revenue growth to surpass $10 million quarterly revenue mark, as annual recurring revenue growth accelerates to 57%.
Global Healthcare Leader Selects Kneat
February 28, 2024 07:17 ET
|
kneat.com, inc.
Kneat has signed a Master Services Agreement with a global provider of critical care products with over 50,000 employees.
Kneat Announces Closing of $20 Million Bought Deal Including Full Exercise of Over-Allotment Option
February 14, 2024 09:04 ET
|
kneat.com, inc.
Kneat announced the closing of its bought deal: it issued 6,153,880 common shares at $3.25 per share for gross proceeds of $20,000,110.
Kneat to Announce 2023 Fourth-Quarter and Fiscal Year Financial Results February 21, 2024
February 13, 2024 17:12 ET
|
kneat.com, inc.
Kneat will announce its Q4 2023 results on February 21, 2024 after market close and host a call for investors the following morning.
Clinical Biomarkers Market Size to Reach USD 63.04 Billion in 2032 | Emergen Research
December 12, 2023 07:31 ET
|
Emergen Research
Vancouver, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The global clinical biomarkers market is expected to reach a market size of USD 63.04 billion at a steady CAGR of 10.2% in 2032, according to latest...
Global Bioprocess Validation Market is anticipated to cross US$ 449.03 Million by 2033 end at an aggressive CAGR of 9.20% | Deep analysis by Future Market Insights, Inc.
March 31, 2023 09:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, March 31, 2023 (GLOBE NEWSWIRE) -- As per the current market research conducted by FMI, the global Bioprocess Validation Market is expected to record a CAGR of 9.20% from 2023 to 2033....